What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? [electronic resource]
Producer: 20150804Description: 83-106 p. digitalISSN:- 1879-0461
- Antineoplastic Agents -- therapeutic use
- Colorectal Neoplasms -- drug therapy
- Humans
- Indoles -- therapeutic use
- Receptors, Fibroblast Growth Factor -- antagonists & inhibitors
- Receptors, Platelet-Derived Growth Factor -- antagonists & inhibitors
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Signal Transduction -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.